Gandhi Jarel K, Roy Chowdhury Uttio, Manzar Zahid, Buck Jochen, Levin Lonny R, Fautsch Michael P, Marmorstein Alan D
1 Department of Ophthalmology, Mayo Clinic , Rochester, Minnesota.
2 Department of Pharmacology, Weill Cornell Medical College , New York, New York.
J Ocul Pharmacol Ther. 2017 Oct;33(8):574-581. doi: 10.1089/jop.2017.0027. Epub 2017 Jul 7.
To validate the increase in intraocular pressure (IOP) caused by soluble adenylyl cyclase (sAC) inhibitors and determine reasons behind variation in IOP measurements performed by tonometry.
C57BL/6J mice were administered DMSO solubilized sAC inhibitors (KH7 or LRE-1) by intraperitoneal injection. Two hours post-treatment, mice were anesthetized with avertin or ketamine/xylazine/acepromazine (KXA). IOP was measured by a rebound tonometer or direct cannulation of the anterior chamber. Spectral-domain optical coherence tomography was used to measure anterior chamber depth and corneal thickness in live mice. Outflow facility was measured in perfused, enucleated mouse eyes.
Compared with DMSO controls, KH7 treatment caused an increased IOP in avertin- and KXA-anesthetized mice when measured by direct cannulation [avertin: 14.4 ± 2.1 mmHg vs. 11.1 ± 1.0 mmHg (P = 0.003); KXA: 14.4 ± 1.0 mmHg vs. 11.3 ± 0.8 mmHg (P < 0.001)] and tonometry [avertin: 10.8 ± 1.4 mmHg vs. 7.4 ± 0.6 mmHg (P < 0.001); KXA: 11.9 ± 0.9 mmHg vs. 10.3 ± 1.7 mmHg (P = 0.283)]. However, treatment with KH7 in nonanesthetized mice showed a significant decrease in IOP measured by tonometry and compared with DMSO-treated animals [13.1 ± 2.6 mmHg vs. 15.6 ± 0.5 mmHg (P = 0.003)]. Both KH7- and DMSO-treated groups anesthetized with avertin showed increased corneal thickness, whereas KH7-treated mice anesthetized with KXA exhibited a shallower anterior chamber compared with untreated mice. KH7 decreased outflow facility by 85.1% in nonanesthetized, enucleated eyes (P < 0.003).
Systemically administered DMSO and anesthesia have significant effects on anterior chamber characteristics, resulting in altered IOP readings measured by tonometry. In the presence of DMSO and anesthesia, tonometry IOP readings should be confirmed with direct cannulation.
验证可溶性腺苷酸环化酶(sAC)抑制剂引起的眼压(IOP)升高,并确定眼压计测量IOP变化背后的原因。
通过腹腔注射向C57BL/6J小鼠给予二甲基亚砜(DMSO)溶解的sAC抑制剂(KH7或LRE-1)。治疗后两小时,用阿佛丁或氯胺酮/赛拉嗪/乙酰丙嗪(KXA)麻醉小鼠。通过回弹眼压计或直接穿刺前房测量IOP。使用光谱域光学相干断层扫描测量活体小鼠的前房深度和角膜厚度。在灌注的摘除眼球中测量房水流出率。
与DMSO对照组相比,通过直接穿刺测量时,KH7治疗使阿佛丁和KXA麻醉的小鼠眼压升高[阿佛丁:14.4±2.1 mmHg对11.1±1.0 mmHg(P = 0.003);KXA:14.4±1.0 mmHg对11.3±0.8 mmHg(P < 0.001)],眼压计测量结果也显示升高[阿佛丁:10.8±1.4 mmHg对7.4±0.6 mmHg(P < 0.001);KXA:11.9±0.9 mmHg对10.3±1.7 mmHg(P = 0.283)]。然而,在未麻醉的小鼠中用KH7治疗时,眼压计测量的IOP与DMSO处理的动物相比显著降低[13.1±2.6 mmHg对15.6±0.5 mmHg(P = 0.003)]。用阿佛丁麻醉的KH7和DMSO处理组均显示角膜厚度增加,而用KXA麻醉的KH7处理小鼠与未处理小鼠相比前房较浅。在未麻醉的摘除眼球中,KH7使房水流出率降低85.1%(P < 0.003)。
全身给予DMSO和麻醉对前房特征有显著影响,导致眼压计测量的IOP读数改变。在存在DMSO和麻醉的情况下,眼压计的IOP读数应用直接穿刺进行确认。